Edinburgh Molecular Imaging Commences Phase II European Cancer Trial
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK, September 20, 2017 – Edinburgh Molecular Imaging (EM Imaging),
Apellis Pharmaceuticals Announces That APL-2 Met Its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
Statistically Significant Slowing of Disease Progression Seen at 12 Months Louisville, Kentucky, August 24, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a
Topas Therapeutics Signs Multi-Year Research and Option Agreement with Lilly Focused on Immune Tolerance
Work will utilize Topas’ novel approach for antigen-specific tolerance induction Lilly has option to in-license and further develop drug candidates produced under the collaboration
Apellis Pharmaceuticals Announces $60 Million Series E Financing
Funding Will Advance Trials of APL-2 in Paroxysmal Nocturnal Hemoglobinuria. Louisville, Kentucky, August 10, 2017 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform
Epidarex Capital Portfolio Company, Confluence Life Sciences, Acquired by Aclaris Therapeutics
August 10, 2017 – Epidarex Capital (“Epidarex”), an early stage life science venture capital firm, is pleased to announce the latest exit from its portfolio with
Aclaris Therapeutics Acquires Confluence Life Sciences, Inc.
Expands pipeline of medicines for the potential treatment of patients with autoimmune disorders. Malvern, PA, August 8, 2017 – Aclaris Therapeutics, Inc. (“Aclaris”) (NASDAQ: ACRS),
Positive Data from APL-2 Studies Show Rapid and Durable Improvements in LDH and Hemoglobin Levels in PNH
Louisville, KY, June 29, 2017 – Apellis Pharmaceuticals, Inc. today provided an update on clinical outcomes in its two ongoing Phase 1b clinical trials with
Groundbreaking Research Into Kinases Using CellOPTIQ From Clyde Biosciences
Highlights from the publication include: Collaboration with AZ on kinase inhibitor induced cardiotoxicity Understanding E-C coupling is essential in kinase research CellOPTIQ® is the only